Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

eFFECTOR Therapeutics, Inc. (EFTR)

0.3936   -0.005 (-1.35%) 12-07 15:59
Open: 0.4 Pre. Close: 0.399
High: 0.4298 Low: 0.38
Volume: 68,137 Market Cap: 16(M)

Technical analysis

as of: 2022-12-07 4:21:49 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.61     One year: 0.72
Support: Support1: 0.37    Support2: 0.31
Resistance: Resistance1: 0.52    Resistance2: 0.62
Pivot: 0.45
Moving Average: MA(5): 0.41     MA(20): 0.47
MA(100): 0.61     MA(250): 2.63
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 11.7     %D(3): 18.1
RSI: RSI(14): 29.2
52-week: High: 9.53  Low: 0.37
Average Vol(K): 3-Month: 107 (K)  10-Days: 58 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EFTR ] has closed above bottom band by 13.0%. Bollinger Bands are 19.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.43 - 0.43 0.43 - 0.44
Low: 0.37 - 0.38 0.38 - 0.38
Close: 0.39 - 0.39 0.39 - 0.39

Company Description

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Headline News

Wed, 07 Dec 2022
Finance Stocks Lead Highs Wednesday; Markets Lower - InvestorsObserver

Fri, 02 Dec 2022
Looking Into eFFECTOR Therapeutics's Return On Capital Employed - eFFECTOR Therapeutics (NASDAQ:EFTR) - Benzinga

Thu, 10 Nov 2022
Save $300 on the Indian eFTR Mini youth bike - MCNews

Wed, 09 Nov 2022
Stocks Lower Wednsday; FTX Fallout Drags Cryptos - InvestorsObserver

Wed, 14 Sep 2022
eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug - Seeking Alpha

Tue, 06 Sep 2022
Indian Motorcycle expands electric youth bike lineup - Powersports Business

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 42 (M)
% Held by Insiders 1.577e+007 (%)
% Held by Institutions 7.9 (%)
Shares Short 218 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.605e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 176.9
Operating Margin (%) -1
Return on Assets (ttm) 131.4
Return on Equity (ttm) -46.8
Qtrly Rev. Growth 3.19e+006
Gross Profit (p.s.) 0.49
Sales Per Share 0.02
EBITDA (p.s.) -0.63
Qtrly Earnings Growth 0.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -24 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 13.57
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 141580
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.